To carry out a comparative assessment of the indices of humoral, cellular immunity and cytokine profile in patients with acute respiratory infections.~Current Program Population: 1500 healthy male and female volunteers, aged of between 18 and 65 will be included in the program.~All included volunteers will be divided into groups:~Group 1 - 750 volunteers who will be vaccinated with BiVac polio vaccine; post-vaccination observation period of 12 months.~Group 2 - 750 volunteers, placebo will be administered, post-vaccination observation period of 12 months.~The probability of getting into one of the two groups for each volunteer will be 50%.
Observational program, double-blind, placebo-controlled to study the preventive efficacy of the BiVac polio (Oral polio vaccine, divalent, live attenuated of types 1 and 3 vaccine against the incidence of acute respiratory infections, including COVID-19